| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.21(B) |
| Last
Volume: |
975,365 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
| Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
| Total People Sold |
7 |
12 |
14 |
18 |
| Total Sell Transactions |
7 |
40 |
65 |
130 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bozic Carmen |
EVP and CMO |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$579,372 |
D/D |
(2,437) |
54,504 |
|
- |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$112,689 |
D/D |
(474) |
16,720 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$836,369 |
D/D |
(3,518) |
62,179 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2022-02-10 |
4 |
D |
$237.74 |
$720,590 |
D/D |
(3,031) |
138,672 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2022-02-02 |
4 |
D |
$243.63 |
$1,529,753 |
D/D |
(6,279) |
110,326 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2022-02-02 |
4 |
AS |
$250.07 |
$736,206 |
D/D |
(2,944) |
57,435 |
|
-3% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
AS |
$247.73 |
$1,171,842 |
D/D |
(4,660) |
65,697 |
|
-3% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
OE |
$86.52 |
$403,183 |
D/D |
4,660 |
70,357 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-02 |
4 |
AS |
$250.04 |
$261,017 |
D/D |
(1,040) |
54,952 |
|
-3% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
66,817 |
116,605 |
|
- |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,941 |
17,194 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,588 |
60,379 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,108 |
65,697 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
67,949 |
141,703 |
|
- |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,566 |
3,960 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,375 |
79,478 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,988 |
56,941 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,638 |
61,566 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,714 |
59,257 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-01 |
4 |
D |
$243.64 |
$128,155 |
D/D |
(526) |
55,992 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,942 |
56,518 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-01-28 |
4 |
AS |
$240.53 |
$1,208,960 |
D/D |
(5,000) |
1,099 |
|
13% |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-01-28 |
4 |
OE |
$127.54 |
$637,700 |
D/D |
5,000 |
6,099 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2021-11-15 |
4 |
AS |
$186.80 |
$6,365 |
D/D |
(34) |
33,589 |
|
38% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2021-11-15 |
4 |
AS |
$186.99 |
$562 |
D/D |
(3) |
41,103 |
|
38% |
|
3277 Records found
|
|
Page 16 of 132 |
|
|
1.92 (0.44%) 
